NCT07282509 2025-12-15
Safety and Efficacy of Paclitaxel Liposome Arterial Infusion Combined With Systemic Therapy for Second-Line Treatment of Advanced Liver Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 1/2 Not yet recruiting
Clinical Trials
4 trialsNCT06746961 2024-12-24
Efficacy and Safety of QL1706 Plus Lenvatinib As 2nd Line Theapy in Patients with Metastatic Esophageal Carcinoma After Disease Progression on ICIs Therapy
The First Affiliated Hospital of Zhengzhou University
Phase 1/2 Not yet recruiting
NCT06409637 2024-05-10
FOLFOX Plus Lenvatinib Adjuvant Therapy for Hepatocellular Carcinoma Post-Liver Transplantation
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 1/2 Not yet recruiting
NCT06140576 2023-11-20
The Efficacy and Safety of Lenvatinib Combined With Sindilimab and Nab-paclitaxel in the First-line Treatment for Recurrent and Metastatic Triple Negative Breast Cancer: a Phase Ib/IIa Clinical Trial.
Zhejiang Cancer Hospital
Phase 1/2 Not yet recruiting